These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38434464)

  • 1. Frequency of Dimethyl Fumarate-Induced Lymphopenia among Omani Patients with Multiple Sclerosis.
    Jaboob A; Asmi AA; Islam MM; Rezvi S; Redha I; Al-Khabouri J; Al-Zakwani I; Al-Qassabi A; Al-Abri H; Gujjar AR
    Sultan Qaboos Univ Med J; 2024 Feb; 24(1):44-51. PubMed ID: 38434464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
    J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
    Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
    Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
    Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
    Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
    Chu L; Balusha A; Casserly C; Berger W; Morrow SA
    Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes.
    Dinoto A; Sartori A; Cheli M; Pasquin F; Baldini S; Bratina A; Bosco A; Manganotti P
    Mult Scler Relat Disord; 2022 Jan; 57():103357. PubMed ID: 35158466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA
    J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
    Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
    Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dimethyl fumarate on lymphocyte subsets.
    Berkovich R; Weiner LP
    Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate.
    Dempsey JP; Wu L; Balshi A; Jun C; Baber U; Sloane JA
    Mult Scler Relat Disord; 2024 Sep; 89():105737. PubMed ID: 39029343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
    Wood CH; Robertson NP; Htet ZM; Tallantyre EC
    Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
    Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
    Dello Russo C; Scott KA; Pirmohamed M
    Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with dimethyl fumarate-induced lymphopenia.
    Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
    J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
    Roar M; Nielsen ARH; Berg JM; Sirakov G; Stilund M; Schäfer J; Ratzer R; Frederiksen J; Asgari N; Ashna SN; Jensen HB; Kant M; Theódorsdóttir Á; Illes Z; Sellebjerg F; Magyari M; Schlosser LM; Nordborg H; Wergeland S; Sejbaek T
    Mult Scler Relat Disord; 2023 Dec; 80():105127. PubMed ID: 37956521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.